Cargando…
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632748/ https://www.ncbi.nlm.nih.gov/pubmed/26473850 http://dx.doi.org/10.3390/ijms161024243 |
_version_ | 1782399087348285440 |
---|---|
author | Egeland, Nina G. Lunde, Siri Jonsdottir, Kristin Lende, Tone H. Cronin-Fenton, Deirdre Gilje, Bjørnar Janssen, Emiel A. M. Søiland, Håvard |
author_facet | Egeland, Nina G. Lunde, Siri Jonsdottir, Kristin Lende, Tone H. Cronin-Fenton, Deirdre Gilje, Bjørnar Janssen, Emiel A. M. Søiland, Håvard |
author_sort | Egeland, Nina G. |
collection | PubMed |
description | Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with estrogen receptor (ER)-independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted. |
format | Online Article Text |
id | pubmed-4632748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-46327482015-11-23 The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients Egeland, Nina G. Lunde, Siri Jonsdottir, Kristin Lende, Tone H. Cronin-Fenton, Deirdre Gilje, Bjørnar Janssen, Emiel A. M. Søiland, Håvard Int J Mol Sci Review Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with estrogen receptor (ER)-independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted. MDPI 2015-10-14 /pmc/articles/PMC4632748/ /pubmed/26473850 http://dx.doi.org/10.3390/ijms161024243 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Egeland, Nina G. Lunde, Siri Jonsdottir, Kristin Lende, Tone H. Cronin-Fenton, Deirdre Gilje, Bjørnar Janssen, Emiel A. M. Søiland, Håvard The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title_full | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title_fullStr | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title_full_unstemmed | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title_short | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients |
title_sort | role of micrornas as predictors of response to tamoxifen treatment in breast cancer patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632748/ https://www.ncbi.nlm.nih.gov/pubmed/26473850 http://dx.doi.org/10.3390/ijms161024243 |
work_keys_str_mv | AT egelandninag theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT lundesiri theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT jonsdottirkristin theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT lendetoneh theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT croninfentondeirdre theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT giljebjørnar theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT janssenemielam theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT søilandhavard theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT egelandninag roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT lundesiri roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT jonsdottirkristin roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT lendetoneh roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT croninfentondeirdre roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT giljebjørnar roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT janssenemielam roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients AT søilandhavard roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients |